OTHER ASIA

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 46% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.

Key Countries and Territories

Hong Kong
Philippines
Singapore
Taiwan

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Asian pharmaceutical sector (excluding China and Japan) grew 7,7% and was valued at USD57 billion as at 31 December 2017.
The pharmaceutical sectors in Hong Kong, Philippines and Singapore (which are Aspen’s key countries in “Other Asia”) grew 10,0%, 1,7% and 5,3% respectively for the year ended 31 December 2017.

Source: December 2017 IMS

STATISTICS

Number of products launched:

3

(2017: nil)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD45 million

3 – 5 years

USD1 million

Number of product recalls:

Nil

(2017: nil)

Average staff turnover:

16,5%

(2017: 25,9%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’million	2018	2017 (CER)	% change
Total	1 401	1 148	22
Regional Brands	330	324	2
Anaesthetics	658	412	60
Thrombosis	151	166	(9)
High Potency & Cytotoxics	262	246	7